Breast Health Global Initiative
A

Metastatic Breast Disease: Treatment and Palliative Care

By Breast Health Global Initiative FEATURING Alexandru Eniu
December 4, 2018
0 Comments
Login to view comments. Click here to Login

Featured Video

22:25
Novartis Oncology

The Importance of Dosing and Patient Adherence in HR+/HER2- mBC

Feat. N. McAndrew

Featured Video

13:03
Novartis Oncology

CDK4/6 Inhibitor Option for HR+/HER2- mBC: Are All CDK4/6 Inhibitors…

Feat. D. Slamon

Related Content

AUTOPLAY
11:31
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, …

Feat. P. Tarantino
28:36
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "eBC Expert Panel Discussion on Key Trials …

Feat. H. Rugo, K. Jhaveri
49:07
SABCS 2022 Conference Coverage

SABCS 2022 Expert Panel Discussion: Practice-Changing Updates

Feat. J. O'Shaughnessy, S. Tolaney, S. Hurvitz, H. Rugo
24:36
ESMO 2022 Conference Coverage

ESMO 2022 Breast Cancer Panel Discussion: Practice-Changing Updates

Feat. H. Rugo, J. O'Shaughnessy
23:58
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "mBC Expert Panel Discussion on Key Trials …

Feat. H. Rugo, K. Jhaveri
18:15
Novartis Oncology

CDK4/6 Inhibitor in Postmenopausal Patients With HR+/HER2- mBC: Anal…

Feat. G. Hortobagyi
17:04
Novartis Oncology

Discussion on Overall Survival Data Across 3 Phase III Trials in HR+…

Feat. G. Hortobagyi
57:44
Vogl, NY

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl
20:42
Total Health

2022 Updates in TNBC

Feat. I. Schlam
05:45
SABCS 2022 Conference Coverage

SABCS 2022 Adjuvant Paclitaxel & Trastuzumab for Node- HER2+ BC:…

Feat. S. Tolaney
03:05
ecancer

ASCO® 2023 Insights: "Phase III NATALEE Trial - Ribociclib + ET…

Feat. D. Slamon
03:24
ecancer

SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…

Feat. V. Kaklamani
13:32
13th Annual Winter Breast Cancer Symposium

2023 Advances in HR+ mBC: CDK4/6i, SERDs, and ADCs

Feat. W. Gradishar
20:16
University of Colorado Cancer Center

Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…

Feat. V. Borges
03:32
UCSF School of Medicine

Management of Abemaciclib-Related Diarrhea in HR+/HER2- eBC

Feat. S. Donahue
07:34
PrecisCa

Summary of the Updated Results of SOFT/TEXT Trials and the Meta-Anal…

Feat. M. Pegram
26:28
2023 West Oncology Conference

Antibody Drug Conjugates for Breast Cancer: The End of Chemotherapy?

Feat. L. Schwartzberg
09:32
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "TROPiCS-02 Phase 3 Study Final OS Analysi…

Feat. S. Tolaney
08:41
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "10-Year Update of the Short-HER Phase III…

Feat. P. Conte
10:54
Yale Cancer Center

De-Escalation of Adjuvant Therapy in Early Stage HER2+ Breast Cancers

Feat. L. Pusztai